Novartis leads Lp(a) drug race as treatments near market
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Lp(a) affects roughly 1 in 5 people and is a cardiovascular risk factor that current lifestyle interventions and medications largely cannot address, according to STAT+.
- Lp(a) levels are driven primarily by genetics, leaving patients with elevated levels few options for reducing the risk.
- Novartis is the front-runner among drugmakers advancing experimental Lp(a)-targeting treatments through late-stage clinical trials.
- Drugmakers are targeting what STAT+ describes as a 'potentially massive market,' with the article's framing emphasizing 'billions at stake' as new treatments near the market.
Why it matters: Roughly 20% of the population carries an inherited cardiovascular risk factor — Lp(a) — with no existing treatment, and Novartis and rival drugmakers are racing to be first to market with therapies that could generate billions in revenue while filling a long-standing gap in heart-disease prevention.
Ask SkimNews
